The relevance of glucose counterregulatory systems to patients with insulin-dependent diabetes mellitus.
Cryer
P E
PE
White
N H
NH
Santiago
J V
JV
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D001342:Autonomic Nervous System Diseases / Q000503:physiopathology; D001786:Blood Glucose / Q000502:physiology*; D001921:Brain / Q000503:physiopathology; D002838:Chromaffin System / Q000503:physiopathology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000503:physiopathology*; D016883:Diabetic Ketoacidosis / Q000209:etiology; D003929:Diabetic Neuropathies / Q000503:physiopathology; D004837:Epinephrine / Q000502:physiology; D005544:Forecasting; D005934:Glucagon / Q000502:physiology; D013006:Growth Hormone / Q000502:physiology; D006801:Humans; D006854:Hydrocortisone / Q000502:physiology; D006943:Hyperglycemia / Q000209:etiology; D007003:Hypoglycemia / Q000139:chemically induced / Q000209:etiology; D007328:Insulin / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use; D013312:Stress, Physiological / Q000150:complications; D013564:Sympathetic Nervous System / Q000503:physiopathology
D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D007328:Insulin; D013006:Growth Hormone; D005934:Glucagon; D006854:Hydrocortisone; D004837:Epinephrine